Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial.
The Journal of clinical psychiatry June 3, 2026 Martin Johnson, Pau Aceves Baldo, Emilio Arbe et al.
In a small open-label trial, ten women with postpartum depression received up to three escalating doses of inhaled GH001 (a synthetic form of 5-MeO-DMT) on a single day. Depressive symptoms, measured on the Montgomery-Asberg Depression Rating Scale, dropped by an average of 35.4 points from a baseline of 36.7 by day 8, and all participants met criteria for both response and remission. Improvements were first noted two hours after the final dose. The treatment was well tolerated, with only mild to moderate side effects, most commonly headache. These preliminary findings suggest GH001 may produce rapid and substantial antidepressant effects in postpartum depression, but larger controlled trials are needed.